Serina Therapeutics, Inc. (SER) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
601 GENOME WAY HUNTSVILLE, AL 35806 |
| State of Incorp. | AL |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 8,706 | 345 | 397 | 261 | 280 | 645 | |||
| Cash and cash equivalents | 8,706 | 345 | 397 | 261 | 280 | 645 | |||
| Restricted cash and investments | 447 | 311 | 330 | 695 | |||||
| Receivables | 65 | 57 | 67 | 6 | 6 | 4 | |||
| Prepaid expense | |||||||||
| Other current assets | |||||||||
| Other undisclosed current assets | 166 | 352 | 230 | 772 | 1,131 | 1,109 | |||
| Total current assets: | 8,937 | 754 | 1,141 | 1,350 | 1,747 | 2,453 | |||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset, after accumulated amortization | 104 | ||||||||
| Operating lease, right-of-use asset | 627 | ||||||||
| Property, plant and equipment | 564 | ||||||||
| Long-term investments and receivables | 10,554 | 10,379 | 10,204 | 10,029 | |||||
| Accounts and financing receivable, after allowance for credit loss | 10,554 | 10,379 | 10,204 | 10,029 | |||||
| Intangible assets, net (including goodwill) | 574 | 607 | 640 | 673 | 705 | 738 | |||
| Intangible assets, net (excluding goodwill) | 574 | 607 | 640 | 673 | 705 | 738 | |||
| Restricted cash and investments | 50 | 50 | 50 | 50 | 50 | 50 | |||
| Total noncurrent assets: | 1,919 | 11,211 | 11,069 | 10,927 | 10,784 | 788 | |||
| TOTAL ASSETS: | 10,856 | 11,965 | 12,210 | 12,277 | 12,531 | 3,241 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 4,013 | 2,176 | 1,671 | 961 | 1,262 | 1,034 | |||
| Accounts payable | 2,605 | 1,413 | 1,172 | 506 | 707 | 568 | |||
| Accrued liabilities | 1,297 | 529 | 293 | 256 | 359 | 273 | |||
| Other undisclosed accounts payable and accrued liabilities | 111 | 234 | 206 | 199 | 196 | 193 | |||
| Debt | 9,770 | 3,672 | 1,526 | 22,943 | 20,042 | 7,646 | |||
| Other liabilities | 144 | ||||||||
| Due to related parties | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 141 | ||
| Other undisclosed current liabilities | 276 | 66 | 7 | 601 | 1,077 | 1,257 | |||
| Total current liabilities: | 14,059 | 5,914 | 3,204 | 24,505 | 22,525 | 10,078 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 693 | 693 | 693 | 10,068 | 10,011 | 10,478 | |||
| Long-term debt, excluding current maturities | 693 | 693 | 693 | 10,068 | 10,011 | 10,478 | |||
| Liabilities, other than long-term debt | 413 | ||||||||
| Operating lease, liability | 413 | ||||||||
| Other undisclosed noncurrent liabilities | |||||||||
| Total noncurrent liabilities: | 1,106 | 693 | 693 | 10,068 | 10,011 | 10,478 | |||
| Total liabilities: | 15,165 | 6,607 | 3,897 | 34,573 | 32,536 | 20,556 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (4,309) | 5,469 | (27,536) | (22,175) | (19,894) | (17,212) | |||
| Common stock | 1 | 4 | 4 | 4 | 4 | ||||
| Common stock held by subsidiary | (250) | (250) | (250) | (250) | |||||
| Additional paid in capital | 1,125 | 136,482 | 100,017 | 99,977 | 99,589 | 98,994 | |||
| Accumulated deficit | (5,435) | (131,013) | (127,557) | (122,156) | (119,487) | (116,210) | |||
| Other undisclosed equity, attributable to parent | 250 | 250 | 250 | 250 | |||||
| Equity, attributable to noncontrolling interest | (111) | (109) | (121) | (111) | (103) | ||||
| Total equity: | (4,309) | 5,358 | (27,645) | (22,296) | (20,005) | (17,315) | |||
| Other undisclosed liabilities and equity | 35,958 | ||||||||
| TOTAL LIABILITIES AND EQUITY: | 10,856 | 11,965 | 12,210 | 12,277 | 12,531 | 3,241 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 5 | 56 | 67 | 9 | 10 | 8 | ||
| Cost of revenue | (1) | (33) | (5) | (1) | (1) | |||
| Gross profit: | 5 | 55 | 34 | 4 | 9 | 7 | ||
| Operating expenses | (2,326) | (3,615) | (2,390) | (1,890) | (2,167) | (1,789) | ||
| Other undisclosed operating income | 73 | |||||||
| Operating loss: | (2,321) | (3,487) | (2,356) | (1,886) | (2,158) | (1,782) | ||
| Nonoperating income (expense) | (7,116) | 29 | (3,033) | (793) | (1,127) | (979) | ||
| Interest and debt expense | 28 | (3,036) | (792) | (1,100) | (978) | |||
| Income (loss) from continuing operations before equity method investments, income taxes: | (9,437) | (3,430) | (8,425) | (3,471) | (4,385) | (3,739) | ||
| Other undisclosed income from continuing operations before income taxes | 34,511 | 22,000 | ||||||
| Income (loss) from continuing operations before income taxes: | (9,437) | 31,081 | (8,425) | (3,471) | (4,385) | 18,261 | ||
| Other undisclosed loss from continuing operations | (28,785) | |||||||
| Income (loss) from continuing operations: | (9,437) | 31,081 | (8,425) | (3,471) | (4,385) | (10,524) | ||
| Other undisclosed net income (loss) | (34,539) | 3,036 | 792 | 1,100 | 7,763 | |||
| Net income (loss): | (9,437) | (3,458) | (5,389) | (2,679) | (3,285) | (2,761) | ||
| Net income (loss) attributable to noncontrolling interest | 2 | (12) | 10 | 8 | 58 | |||
| Net income (loss) attributable to parent: | (9,437) | (3,456) | (5,401) | (2,669) | (3,277) | (2,703) | ||
| Undistributed earnings (loss) allocated to participating securities, basic | ||||||||
| Other undisclosed net income (loss) available to common stockholders, basic | (15,518) | |||||||
| Net income (loss) available to common stockholders, diluted: | (9,437) | (3,456) | (5,401) | (2,669) | (3,277) | (18,221) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (9,437) | (3,458) | (5,389) | (2,679) | (3,285) | (2,761) | ||
| Other comprehensive loss | (3,277) | (2,703) | ||||||
| Other undisclosed comprehensive income | 10 | |||||||
| Comprehensive income (loss): | (9,437) | (3,458) | (5,389) | (2,669) | (6,562) | (5,464) | ||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | 2 | (12) | 10 | 8 | 58 | |||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 3,269 | 2,645 | ||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (9,437) | (3,456) | (5,401) | (2,659) | (3,285) | (2,761) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.